Allopurinol 100mg and 200mg tablets
Allopurinol is a medicine that is used to treat gout.
What is changing?
The funded brand of allopurinol will change from Apo-Allopurinol to Allopurinol-Apotex.
When will the change occur?
- From 1 December Allopurinol-Apotex will be fully subsidised and listed on the Pharmaceutical Schedule.
- From 1 June 2017 only Allopurinol-Apotex will be fully funded and Apo-Allopurinol will no longer be available.
Will the new brand work the same?
Yes. Only the brand of your medicine is changing. Allopurinol-Apotex will have the same amount of active ingredient, allopurinol. This means that you should have the same effect from taking Allopurinol-Apotex as you do taking Apo-Allopurinol.
Medsafe, the agency that approves medicines for use in New Zealand, carefully considered the safety and effectiveness of Allopurinol-Apotex before approving it.
You shouldn’t notice any difference when you change to Allopurinol-Apotex. If you do notice any changes of side effects, please talk with your doctor about it.
Will I still be able to get Apo-Allopurinol after 1 June 2017
After 1 June 2017, we cannot guarantee Apo-Allopurinol will be available.
Apotex, the supplier of both Apo-Allopurinol and Allopurinol-Apotex, has decided it will no longer supply Apo-Allopurinol in New Zealand.
Will the tablets look different?
Where can I get more information?
If you would like more information about the change you can contact PHARMAC on firstname.lastname@example.org.
Last updated: 26 October 2017